Stocks began the morning deep in the red as investors continue to grapple with the implications of persisting inflation pressures and expectations of an aggressive Fed policy tightening campaign. Meanwhile, cases of monkeypox are escalating worldwide, forcing the CDC to raise its guidance. This morning the CDC announced it has stepped up its monkeypox alert to level 2, urging travelers to take extra precautions as global cases surpass 1,000.
Our featured company has been gaining attention as concerns about monkeypox outbreaks worsen in the U.S. and around the globe.
The small-cap vaccine maker Siga Technologies (SIGA), whose research has mainly been funded by the U.S. government to address the threat of biological weapons, has developed an antiviral known as tecovirimat or TPOXX, which the European Medicines Agency recently approved not only for monkeypox but also for cowpox and smallpox.
“As you might imagine, a number of the jurisdictions where cases are being found have contacted us and are interested in acquiring the drug as soon as possible,” Dennis Hruby, chief scientific officer at Siga Technologies, previously told Euronews Next. “Our drug will stop further progression of the disease and then allow your natural immune system to kick in and eradicate the virus,” he added.
On May 19th, the company announced that it had earned FDA approval for the intravenous form of TPOXX for the treatment of Smallpox, calling the IV formula “an important option for those who are unable to swallow the oral capsules of TPOXX.” Oral TPOXX is already being administered in the US, Canada, and Europe to treat smallpox, and the IV formulation was recently cited in the U.S. president’s budget request as being used to treat a patient in the U.S. with monkeypox, the company noted. SIGA’s share price has gained 40% over the past month. With TPOXX gaining hold around the globe and plenty of untapped potential, we’ll be keeping an eye on this stock in the weeks to come.
Where to invest $1,000 right now...
Before you consider buying Siga Technologies, you'll want to see this.
Investing legend, Keith Kohl just revealed his #1 stock for 2022...
And it's not Siga Technologies.
Jeff Bezos, Peter Thiel, and the Rockefellers are betting a colossal nine figures on this tiny company that trades publicly for $5.
Keith say’s he thinks investors will be able to turn a small $50 stake into $150,000.
Find that to be extraordinary?
Click here to watch his presentation, and decide for yourself...
But you have to act now, because a catalyst coming in a few weeks is set to take this company mainstream... And by then, it could be too late.
Click here to find out the name and ticker of Keith's #1 pick...
The #1 stock for 2023
The #1 Stock for 2023
According to former Goldman Sachs executive, Nomi Prins…
Americans who are hoping for a ‘return to normal’ are going to be shocked when they see what happens next in America.
She says, “If you’re betting your job, savings, or retirement accounts on a return to ‘normal’ you’re about to be left behind by a brand-new crisis few see coming.”
Go here now to see America’s next crisis
Legacy Research:
A Return to Normal? PhD Economist: “Don’t Bet on It”
According to former Goldman Sachs executive, Nomi Prins…
Americans who are hoping for a ‘return to normal’ are going to be shocked when they see what happens next in America.
She says, “If you’re betting your job, savings, or retirement accounts on a return to ‘normal’ you’re about to be left behind by a brand-new crisis few see coming.”
Go here now to see America’s next crisis